Estudio observacional de eficacia y seguridad del cambio de insulina NPH a glargina en atención primaria. Estudio LAURA

Soriguer, 2012, Prevención de la diabetes mellitus tipo2, Med Clin (Barc), 139, 640, 10.1016/j.medcli.2012.03.015 Turner, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 1995, United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years, BMJ, 310, 83, 10.1136/bmj.310.6972.83 Inzucchi, 2012, Management of hyperglycaemia in type2 diabetes: A patient-centered approach, Diabetes Care, 35, 1364, 10.2337/dc12-0413 Jabbour, 2008, Primary care physicians and insulin initiation: Multiple barriers, lack of knowledge or both?, Int J Clin Pract, 62, 845, 10.1111/j.1742-1241.2008.01757.x Linn, 2008, Nocturnal glucose metabolism after bedtime injection of insulin Glargine or neutral protamine Hagedorn insulin in patients with type2 diabetes, J Clin Endocrinol Metab, 93, 3839, 10.1210/jc.2007-2871 Vinagre, 2012, Control of glycemia and cardiovascular risk factors in patients with type2 diabetes in primary care in Catalonia (Spain), Diabetes Care, 35, 774, 10.2337/dc11-1679 Alvarez Guisasola, 2008, Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study, Diabetes Obes Metab, 10, 25, 10.1111/j.1463-1326.2008.00882.x Fonseca, 2011, An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia, Diabetes Obes Metab, 13, 814, 10.1111/j.1463-1326.2011.01412.x Rosenstock, 2001, Basal insulin therapy in type2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin, Diabetes Care, 24, 631, 10.2337/diacare.24.4.631 2003, Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type2 diabetic patients, Diabet Med, 20, 545, 10.1046/j.1464-5491.2003.00999.x Massi Benedetti, 2003, A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type2 diabetes, Horm Metab Res, 35, 189, 10.1055/s-2003-39080 Yki-Jarvinen, 2006, 2006 Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study, Diabetologia, 49, 442, 10.1007/s00125-005-0132-0 Delgado, 2012, Outcomes with insulin glargine in patients with type2 diabetes previously on NPH insulin: Evidence from clinical practice in Spain, Int J Clin Pract, 66, 281, 10.1111/j.1742-1241.2011.02880.x Lee, 2012, Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: Results from a pooled analysis, J Am Geriatr Soc, 60, 51, 10.1111/j.1532-5415.2011.03773.x Barnett, 2010, Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes, Int J Clin Pract, 64, 1121, 10.1111/j.1742-1241.2009.02332.x Williams, 2011, Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type2 diabetes mellitus, Diabetes Res Clin Pract, 91, 363, 10.1016/j.diabres.2010.12.027 Cryer, 2002, Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes, Diabetologia, 45, 937, 10.1007/s00125-002-0822-9 Cefalu, 2002, Evaluation of alternative strategies for optimizing glycemia: Progress to date, Am J Med, 113, 23S, 10.1016/S0002-9343(02)01278-0 Polonsky, 2005, Psychological insulin resistance in patients with type2 diabetes, Diabetes Care, 28, 2543, 10.2337/diacare.28.10.2543 Karter, 2010, Barriers to insulin initiation: The translating research into action for diabetes insulin starts project, Diabetes Care, 33, 733, 10.2337/dc09-1184 Gómez-Peralta, 2012, Glycaemic control in patients with type2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: An observational study, Int J Clin Pract, 66, 959, 10.1111/j.1742-1241.2012.03000.x Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743 Berlie, 2010, Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly, Ann Pharmacother, 44, 712, 10.1345/aph.1M551 Menéndez, 2012, El nuevo «Position statement of the ADA/EASD on the management of hyperglycemia in type 2 diabetes». Perspectiva desde el Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes, Av Diabetol, 28, 79, 10.1016/j.avdiab.2012.07.001 Avilés-Santa, 1999, Effects of metformin in patients with poorly controlled, insulin-treated type2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 131, 182, 10.7326/0003-4819-131-3-199908030-00004 Bretzel, 2008, Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial, Lancet, 371, 1073, 10.1016/S0140-6736(08)60485-7 Riddle, 2011, Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type2 diabetes, Diabetes Care, 34, 2508, 10.2337/dc11-0632